CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
bevacizumab +1 morebiological
Likely dose
Bevacizumab IV (dose not specified in available text)AI-extracted
Key inclusion· 5
  • ✓Histologically confirmed persistent or recurrent squamous cell carcinoma of the cervix
  • ✓Prior treatment: at least 1 but no more than 2 prior cytotoxic chemotherapy regimens for advanced, metastatic, or recurrent disease (chemotherapy as radio-sensitizer does not count)
  • ✓Documented disease progression
  • ✓At least 1 unidimensionally measurable lesion (≥20 mm by conventional imaging or ≥10 mm by spiral CT)
Key exclusion· 7
  • ✕CNS disease, including primary or metastatic brain tumors
  • ✕Known bleeding disorder or coagulopathy; other active bleeding or pathologic condition conferring high risk of bleeding
  • ✕Uncontrolled hypertension, myocardial infarction or unstable angina within 6 months, NYHA grade II-IV heart failure, serious cardiac arrhythmia, grade II or greater peripheral vascular disease, stroke within 5 years
  • ✕Serious nonhealing wound, ulcer, or bone fracture

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00025233
NCT00025233Phase 2Completed
CompareCT.gov

A Phase II Trial of Bevacizumab (rhuMAB VEGF) (NSC #704865) in the Treatment of Persistent and Recurrent Squamous Cell Carcinoma of the Cervix (Group A)

National Cancer Institute (NCI)·interventional·Posted Jan 27, 2003·Updated Jul 24, 2019

In Brief

A Phase 2 clinical trial evaluating bevacizumab and laboratory biomarker analysis for Cervical Squamous Cell Carcinoma and Recurrent Cervical Cancer. Completed, enrolled 50 participants across 1 site.

Detailed Summary

This phase II trial is to see if bevacizumab works in treating patients who have persistent or recurrent cancer of the cervix. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Squamous Cell Carcinoma, Recurrent Cervical Cancer
CountriesUnited States
CollaboratorsGynecologic Oncology Group

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartApr 1, 2002
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 23.4 years ago

Interventions

bevacizumabbiological

Given IV

laboratory biomarker analysisother

Correlative studies